MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Falls characteristics of male and female patients with Parkinson’s disease (PD)

    G. Alg, A. Chatterjee, F. Zahir (Reading, United Kingdom)

    Objective: To compare Falls risk characteristics in male and female PD patients attending a multidisciplinary Movement disorders clinic. Background: Parkinson’s disease is commoner in males.…
  • 2017 International Congress

    Death in patients with Parkinson’s disease – an observational study

    R. Mappilakkandy, A. Pieris, D. Miodrag, A. Chunduri (Northampton, United Kingdom)

    Objective: We aimed to analyse the major cause and contributory reasons for death in patients with Parkinson’s disease (PD) who were known to our PD…
  • 2017 International Congress

    Social importance of care and rehabilitation in restoring of psycho-emotional and movement deficits in Parkinsonism.

    M. Sanoeva, M. Gulova, M. Avezova, N. Mansurova (Bukhara, Uzbekistan)

    Objective: To investigate the impact of new devised program for care and rehabilitation for patients with Parkinsonism. Background: Monitoring and rehabilitation, proper care, psychological support…
  • 2017 International Congress

    Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)

    L. Adar, T. Rachmilewitz Minei, Y. Cohen, S. Oren (Rehovot, Israel)

    Objective: To compare levodopa PK, derived from ND0612 (a proprietary liquid levodopa/carbidopa formulation designed for subcutaneous (SC) administration) with Levodopa/Carbidopa Intestinal Gel (LCIG). Background: While…
  • 2017 International Congress

    Acquisition, Validation and Preprocessing of Wrist-Worn Sensor Data in Patients with Parkinson’s Disease and Healthy Controls

    D. Pichler, M. Lang, D. Kulić, F. Pfister, G. König, T. Um, A. Ahmadi, S. Endo, F. Achilles, K. Abedinpour, K. Bötzel, A. Ceballos-Baumann, S. Hirche, U. Fietzek (Munich, Germany)

    Objective: We describe relevant aspects and data processing steps for accelerometry and gyroscopy recordings made with a wrist-worn low-cost sensor device. In order to generalize…
  • 2017 International Congress

    Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson’s Disease

    C.-M. Chen, K.-H. Chang, Y.-R. Wu, M.-L. Cheng (Taoyuan, Taiwan)

    Objective: The purpose of this study was to identify potential plasma metabolic biomarkers for Parkinson’s disease (PD) Background: PD, characterized by a slowness of movement…
  • 2017 International Congress

    Tandem Standing

    E. Okuyucu, E. Dogru Huzmeli, S. Colakoglu Yesildag, I. Huzmeli (Hatay, Turkey)

    Objective: The aim of this study is to learn, patients who can’t make tandem standing fall more or not? Background: Falls occur more often with…
  • 2017 International Congress

    Innovative recruitment strategies accelerate enrollment of genetic mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI)

    V. Arnedo, S. Lasch, T. Foroud, L. Heathers, J. Martorelli, C. Halter, N. Ryerson, J. Verbrugge, L. Cook, K. Marek (New York, NY, USA)

    Objective: Determine feasibility of digital recruitment strategies, centralized screening, and a dedicated referral coordinator to enroll participants with LRRK2 or GBA mutations into PPMI, a…
  • 2017 International Congress

    Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.

    T.G. Study Group (Bristol, United Kingdom)

    Objective: Assesing the neurorestorative effect of GDNF.  Background: GDNF is a potent neurotrophic factor. A previous placebo-controlled trial, however, at 6 months, failed to demonstrate…
  • 2017 International Congress

    Feasibility of using a smartphone application for the objective evaluation of Parkinson disease

    R. Schneider, J. Adams, M. Elson, C. Tarolli, S. Sharma, A. Glidden, T. Felong, A. Zhan, R. Korn, S. Goldenthal, D. Harris, M. Xiong, M. Little, K. Biglan, R. Dorsey (Rochester, NY, USA)

    Objective: To determine the feasibility, reliability, and value of using a smartphone application to longitudinally track motor and non-motor features of Parkinson disease (PD).  Further,…
  • « Previous Page
  • 1
  • …
  • 55
  • 56
  • 57
  • 58
  • 59
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley